Hicks v. CHARLES PFIZER & CO. INC.

368 F. Supp. 2d 628, 2005 U.S. Dist. LEXIS 8325, 2005 WL 1077554
CourtDistrict Court, E.D. Texas
DecidedMarch 8, 2005
Docket2:04-cv-00201
StatusPublished
Cited by1 cases

This text of 368 F. Supp. 2d 628 (Hicks v. CHARLES PFIZER & CO. INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Hicks v. CHARLES PFIZER & CO. INC., 368 F. Supp. 2d 628, 2005 U.S. Dist. LEXIS 8325, 2005 WL 1077554 (E.D. Tex. 2005).

Opinion

MEMORANDUM AND ORDER

CRONE, District Judge.

Pending before the court is Defendants Wyeth Laboratories, Inc., Wyeth-Ayerst Laboratories, Inc., Wyeth Lederle Vaccines, Wyeth-Ayerst Pharmaceuticals, Lederle Laboratories, Inc., Lederle Laboratories, American Cyanamid Company, American Home Products Corporation, Wyeth, Wyeth Holdings, Inc., and Wyeth Pharmaceuticals, Inc.’s (collectively, “Wyeth”) Motion for Summary Judgment (# 66). Wyeth seeks summary judgment on Plaintiffs Karen Hicks (“Karen”) and Benny Hicks’s (collectively, “the Hicks”) personal injury action asserting claims for products liability, negligence, fraud, and breach of warranty, arising out of Karen’s alleged ingestion of doses of oral polio vaccine, which the Hicks assert caused Karen to develop a brain tumor. Having reviewed the pending motion, the submissions of the parties, the pleadings, and the applicable law, the court is of the opinion that summary judgment is warranted.

I. Background

In June 2001, Karen was diagnosed with a brain tumor, which she alleges was caused by oral polio vaccine (“OPV”) that she received when she was a child. The Hicks contend that during the manufacturing process, the - OPV was contaminated with simian virus 40 (“SV 40”) while being cultured in tissue from monkey kidneys. SV 40 has allegedly been linked to brain tumor formation and cancer in humans, and the Hicks maintain that tests on the tissue of Karen’s tumor revealed the presence of SV 40 deoxyribonucleic acid.

In 1962, the Jefferson County Medical Society (“Medical Society”) sponsored a massive public health campaign, Project XP, to eradicate polio and provided free OPV to any resident over six weeks of age who wished to receive the vaccine. The *630 Project XP campaign was administered in 1962 in three phases-September 9 (Type I), October 21 (Type III), and December 2 (Type II). Three drops of the OPV were placed on a sugar cube, which the recipient then ingested. Karen claims to have participated in Project XP and to have ingested the three separate sugar cube vaccinations in 1962, when she was approximately five years of age.' Karen- further alleges that she received one or two more doses of OPV from plastic dispettes at her physician’s office in 1968 and 1971.

The Hicks filed suit in the 58th Judicial District Court of Jefferson County, Texas, on February 19, 2004, asserting that one or more of the thirty-three named defendants manufactured the OPV Karen received. On April 8, 2004, the case was removed to federal court on the basis of diversity jurisdiction. See 28 U.S.C. § 1332. The court held a scheduling conference on July 9, 2004, and-the parties agreed to an interim schedule in order to conduct discovery to determine which, if any, of the named defendants manufactured the vaccine that allegedly caused Karen’s brain tumor. Thé' court’s order directed the Hicks to disclose all information and documents in their possession “relevant to the product identification issue” and allowed the defendants to depose Karen on the limited issue of product identification. Additionally, the court ordered the defendants to provide all documents in their possession relating to the distribution or sale of polio vaccine in Jefferson County, Texas, during the time periods identified by the Hicks.

As a result of the product identification discovery, the Hicks dismissed from this action all but ten of the defendants. Following the dismissal, the remaining defendants were corporate entities all affiliated, through acquisition or .merger, with Wyeth. On February 18, 2005, the Hicks filed a motion for leave to amend their complaint to add Charles Pfizer & Company, Inc., Pfizer, Ltd., and Pfizer Inc. (collectively, “Pfizer”), as defendants in this case. The Hicks had previously moved to dismiss the Pfizer entities without prejudice on January 7, 2005, which the court granted on January 13, 2005. On March 8, 2005, the court granted the Hicks’ motion to amend their complaint to add the Pfizer companies as defendants once again.

Wyeth seeks summary judgment on the grounds that, after extensive product identification discovery, the Hicks are unable to identify the manufacturer of the OPV Karen received or to link Wyeth to the OPV delivered to Jefferson County during the relevant time periods. As a consequence, according to Wyeth, the Hicks cannot prove the causation element of their claims.

II.. Analysis

A. Summary Judgment Standard

Rule 56(c) of the Federal Rules of Civil Procedure provides that summary judgment “shall be rendered forthwith if the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and - that the moving party is entitled to judgment as a matter of law.” Fed. R. Crv. P. 56(c). The parties seeking summary judgment bear the initial burden of informing the court of. the basis for their motion and identifying those portions of the pleadings, depositions, answers to interrogatories, admissions on file, and affidavits, if any, which they believe demonstrate the absence of a genuine issue of material fact. See Celotex Corp. v. Catrett, 477 U.S. 317, 323, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986); Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247-48, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986); Martinez v. Schlumberger, Ltd., 338 F.3d 407, 411 (5th *631 Cir.2003); Terrebonne Parish Sch. Bd. v. Mobil Oil Corp., 310 F.3d 870, 877 (5th Cir.2002); Colson v. Grohman, 174 F.3d 498, 506 (5th Cir.1999).

“A fact is ‘material’ if it ‘might affect the outcome of the suit under governing law.’ ” Bazan v. Hidalgo County, 246 F.3d 481, 489 (5th Cir.2001) (emphasis in original) (quoting Anderson, 477 U.S. at 248, 106 S.Ct. 2505); see Harken Exploration Co. v. Sphere Drake Ins. PLC, 261 F.3d 466, 471 (5th Cir.2001); Merritt-Campbell, Inc. v. RxP Prods., Inc., 164 F.3d 957, 961 (5th Cir.1999); Burgos v. Southwestern Bell Tel. Co., 20 F.3d 633, 635 (5th Cir.1994). “An issue is ‘genuine’ if it is real and substantial, as opposed to merely formal, pretended, or a sham.” Bazan, 246 F.3d at 489 (emphasis in original). Thus, a genuine issue of material fact exists “if the evidence is such that a reasonable jury could return a verdict for the nonmoving party.” Anderson, 477 U.S. at 248, 106 S.Ct. 2505; accord Harken Exploration Co., 261 F.3d at 471; Merritt-Campbell, Inc., 164 F.3d at 961. The moving parties, however, need not negate the elements of the nonmovants’ case. See Wallace v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Garcia v. Pfizer Inc.
268 F. App'x 270 (Fifth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
368 F. Supp. 2d 628, 2005 U.S. Dist. LEXIS 8325, 2005 WL 1077554, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hicks-v-charles-pfizer-co-inc-txed-2005.